First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Evolving Treatments for Advanced Renal Cell Carcinoma: ASCO 2023 and Beyond

Peer Exchange

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

Overview of First-Line Combination Therapy in Advanced Clear Cell RCC

Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC

Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies  

Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC

Selecting Therapy for a Real-World Patient With Clear Cell RCC

Rationale Behind Discontinuing IO Therapy in Clear Cell RCC

Second-Line Treatment Armamentarium in Clear Cell RCC

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

Renal Cell Carcinoma: Future Evolutions in Care

Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)

Available Treatment Options for Patients with Advanced RCC

Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC

Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC

Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

Future Perspectives in the Treatment of Advanced RCC